Oncolytics Biotech Inc T.ONC

G12D/G12V KRAS mutation in PC & CRC patients respond to Pela

[Noteable]

The KRAS G12D mutation is present in more than one in three pancreatic cancers, about one in ten colorectal cancers, and in several other cancer types. 

https://stockhouse.com/companies/bullboard?symbol=t.onc&threadid=35639972

Mutations in both KRAS and TP53 genes are found in around 80% and 70% of all human pancreatic cancers respectively.

Mutant KRAS, found in 95% of pancreatic cancers, leads to an activated protein that aberrantly triggers many downstream signaling pathways. Mutant TP53 results in the loss of the proteins’ tumor suppressor function, leaving the mutant protein capable of fueling additional oncogenic processes, such as metastasis.

ONCYs pelareorep demonstrates to be effective in the knockdown of both KRAS (G12D/G12V KRAS mutations) and p53 gene activity, and ultimately effective in the treatment of pancreatic and GI cancers

More than half the CRC patients that responded to pelareorep had either a G12V or a G12D mutation (exon 2, codon 12, KRAS gene).

https://aacrjournals.org/mct/article/19/5/1148/274337/Elucidation-of-Pelareorep-Pharmacodynamics-in-A

[Noteable]

https://stockhouse.com/companies/bullboard/t.onc/oncolytics-biotech-ord-shs?postid=35673228

[Noteable]

One of the things that makes pancreatic cancers so hard to treat is that the tumor cells create a dense web of proteins and noncancerous cells around them. This web, which is part of what is called the tumor microenvironment, helps the tumor cells grow and impairs the immune system’s ability to attack them. When a treatment is highly effective in killing tumor cells, “you usually trigger

[Noteable]

Pelareorep's switching off KRAS G12D induces expression of the Fas pathway, reversing early tumor growth, increasing CD8+ T cell infiltration, decreasing myeloid infiltration,  the reprogramming of the tumor microenvironment in both early- and late-stage tumors and the elimination of established tumors upon the activation of CD8+ T cells. Combining various immune checkpoint inhibitors (i

[Noteable]

Should read  .... Mirati Therapeutics' KRAS G12C inhibitor in NSCLC

[fox7mf]

It's unbelievable the attention MRTX gets from BP, analysts and all, and how little Oncy receives when we have so much going for us. Not that the following means much, but SWS has a fair value of $331 attributable to MRTX and Oncy $44. The investment world needs to wake up to Oncy.

[Noteable]

Well foxy, then start telling the world, rather than complaining about it.

[fox7mf]

I'll wait for those responsible for business development to do so, who have thus far failed miserably endeavoring to create shareholder value. Are they capable? I'm not convinced.

[Noteable]

Instead you'd rather complain, do I have that right? And if your not convinced, why are you then here, if not other than to be an annoyin Jack Russell.

[Noteable]

... you're ...

[fox7mf]

It is my right. As it is yours to petulantly shoot down anyone who's opinion doesn't suit your narrative. Ignore me. 

[Buckhenry]

What's the world coming to. Pumpers having a lovers quarrel over price...   I think there is to much inbreeding and it's causing mutants.  

[fox7mf]

MRTX acquired by BMY for $4.8b usd.

[Noteable]

My ... how quickly things change and puts other Big Pharma companies play,  which adds muscle to the thought that multiple Big Pharma companies are after late stage biopharma assets, and are willing to pay premium pricess to close the deal, making ONCY's platform technology in pelareorep more attractive.

[Lesalpes29]

ONC has not the same pipeline if I'm reading well. Do we still have a buyout price at 10 billions? I stop there. GL

[fox7mf]

Hey Note. In your studied opinion, would you be inclined to believe Oncy should get more or less or in the neighborhood of MRTX in a buyout? Just curious. Thx in advance. 

[Noteable]

More due to a wider application as a platform in cancer therapy.

[Noteable]

Supplementally pelareorep (reovirus) induces apoptotic cell death via induced Fas signaling. https://www.oncotarget.com/article/23361/text/

[fox7mf]

Where's the buyout? Where's the partner? What institution purchased all those shares? Where is the signed definitive agreement with Pancan? Where is FDA AA? Anybody else fed up with being kept in the dark? Happy Thanksgiving Canadians!!

[Noteable]

June 2021 paper - Transcriptome Signature of Immune Cells Post Reovirus Treatment in KRAS Mutated Colorectal Cancer Reovirus propagates with high efficiency in KRAS mutated colorectal cancer (CRC). About 45–50% of CRC patients possess a KRAS mutation. Oncolytic reovirus treatment in combination with chemotherapy was tested in patients possessing KRAS mutated metastatic CRC. MicroRNAs

[Noteable]

Now under correct subject title: November 21, 2023 - Timothy Yap, Ph.D., used to see patients nearing the end of their cancer journey in his phase 1 department at the University of Texas' MD Anderson Cancer Center. Either they fit into a phase 1 trial, or they were off to hospice for end-of-life care.  Things have changed, and the situation at his department is a little more

[Noteable]

December 15, 2023 - https://aacrjournals.org/clincancerres/article/29/24/5012/731670/Facts-and-Hopes-on-RAS-Inhibitors-and-Cancer

[Noteable]

December 15, 2023 - Translational Relevance Pelareorep (PELA) is an oncolytic virus formulation that is currently being investigated for multiple myeloma therapy. Our study shows that combination PELA, bortezomib, and dexamethasone therapy is safe, well-tolerated, and induces an inflammatory response in patients with multiple myeloma characterized by significant T and natural killer cell

[Noteable]

January 10. 2024 - Elicio Therapeutics, the makers of ELI-002, a new vaccine that works by targeting two genetic mutations of KRAS genes, specifically KRAS G12D and KRAS G12R, and built of their Amphiphile (AMP) platform, reported on a phase 1 trial in pancreatic and colorectal cancers, that was conducted by researchers at The University of Texas MD Anderson Cancer Center.

[Noteable]

October 2023 - " The data from [ONCY's Phase 2 Goblet study] show a correlation between the expansion of TIL-specific clones and tumor response, which provides compelling support for the use of pelareorep-based therapies in immunologically "cold" tumors. In particular, these data, along with the impressive clinical results, support the ability of pelareorep-checkpoint

[Noteable]

The ELI-002 vaccine is being indicated early and following post surgical treatment of pancreatic or CRC, prior to advanced disease setting, and before onset of tumor immune resistance. ONCY's pelareorep has demonstrated effectiveness in advanced/metastatic pancreatic cancer, for example, where no other effective treatment is currently available.

[Noteable]

In 2021 Titto Augustine, Sanjay Goel, et al. found for the first time that immune-insensitive MSS tumors that account for 85% of all CRC can be effectively converted to immunotherapy-sensitive cancers by introducing reovirus to the therapeutic regimen. They reported that their data confidently establishes that reovirus sensitizes MSS tumors to anti-PD-1 therapy via increasing the

[Noteable]

In 2021 Titto Augustine, Sanjay Goel, et al. found for the first time that immune-insensitive MSS tumors that account for 85% of all CRC can be effectively converted to immunotherapy-sensitive cancers by introducing reovirus to the therapeutic regimen. They reported that their data confidently establishes that reovirus sensitizes MSS tumors to anti-PD-1 therapy via increasing the expression of PD

[CMHarring218431]

Very interesting that you mention Dr Sanjay Goel. Because of him I take a daily supplement of French grape seed extract. He and his team have studied and reported remarkable test results that show this particular extract helps prevent cancers, protects the heart, and strengthens the immune system. Sounds like what you hear about blueberries etc... but he claims it is many, many more times powerful

[Noteable]

Dr. Sanjay Goel (medical oncologist at the Albert Eienstein College of Medicine) AND is NOT Ajay Goel (a poet and the proponent of naturopathy and grape seed extract.) https://cinj.org/sanjay-goel-md-ms

[CMHarring218431]

Dr Ajay Goel , M.S., Ph.D is more than a poet and proponent of natural food remedies. He has quite the reputation as a cancer researcher and his clinical research has proven the the effectiveness of botanical medicines in helping to prevent multiple cancers. His work is definitely worth a look imo

[Noteable]

Ajay Goel PhD is not Dr. Sanjay Goel, M.D. and medical oncologist at the Albert Einstein College of Medicine in New York City 

[Noteable]

Ajay Goel was the owner health food stores and dietary supplement companies

[Noteable]

July 30, 2024 - Incyte's latest list of discontinued assets includes both of Incyte’s oral, small-molecule PD-L1 inhibitors that were being assessed in phase 1 trials. One of these, INCB99280, was being evaluated in an early-stage solid tumor trial, and the biotech had already set out plans for a phase 1/1b trial in KRASG12C-mutated solid tumors in combination with Bristol Myers Squibb’s

[Noteable]

July 31, 2024 - ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the achievement of $100 million in milestones from Incyte Corporation related to development progress of ZYNYZ®

[Noteable]

May 2024 -  The Efficacy of Immune Checkpoint Inhibitors in Microsatellite Stable Colorectal Cancer:  while ICI monotherapy has limited efficacy in MSS CRC, combination strategies hold promise to enhance survival outcomes n 2021 Titto Augustine, Sanjay Goel, et al. found for the first time that immune-insensitive MSS tumors that account for 85% of all CRC can be effectively converted

[Noteable]

November 24, 2023 - China's Innovent Biologics files first NDA for a KRAS G12C inhibitor with China's Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) and is anticipated to benefit more lung cancer patients harbouring KRAS G12C mutation after approval. Innovent is also exploring the potential of IBI351 in combination therapy

[Noteable]

The KRAS G12D mutation is present in more than one in three pancreatic cancers, about one in ten colorectal cancers, and in several other cancer types.  The KRAS protein normally acts like an on–off switch. In response to certain signals, it becomes activated and tells the cell to grow and divide. When the signals are no longer present, it turns off. However, some mutant forms of

[venture009]

Good info. Interesting that ONCY gets no recognition or coverage for their effectiveness in treating these difficult KRAS cancers. This has always been ONCY's problem, getting influential analysts to pay attention. 

[CMHarring218431]

Absolutely, Venture! Promotion is key from reliable and respected sources. Not hype from retail investors, day traders etc..... just good old positive vibes from industry experts,  Now, if Noteable were one of those individuals.....his contributions would have put us on the radar and given us some positive momentum 

[Noteable]

August 22, 2024 - China approves KRAS G12C inhibitor developed by Chinese owned Innovent operating in San Francisco and partnered with the People's Liberation Army of China and MD Anderson Cancer Center, in Houston, TX. The NDA approval is based on the results from a single-arm registrational Phase 2 clinical study (NCT05005234) intended to evaluate the efficacy and safety of fulzerasib

[Noteable]

September 25, 2024 - An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure.  a fixed-dose combination of Keytruda and an anti-LAG-3 antibody failed to improve overall survival. An earlier colorectal cancer study supported full FDA approval of Keytruda in people with microsatellite instability-high solid tumors

[Noteable]

October 02, 2024 - The clinical ranks for the development of a KRAS G12D inhibitor will now be swelled by Lilly’s LY3962673, which had preclinical data at this year’s AACR, and which has just entered phase 1. Pfizer’s pan-KRAS challenger, PF-07934040, entered its first-in-human study in July, and now two other newcomers, BeiGene and Lilly, have joined the fray. The projects in